Sickle Cell Disease

IRB #H-35777/ UPMC #PRO15110016 (STERIO-SCD): A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients with Sickle Cell Diseases

IRB #H-36459/ BMT CTN #1503 (STRIDE-2): A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults With Severe Sickle Cell Disease

IRB #H-39245/ Novartis #SEG101 (STAND): A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus Placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises (STAND)

Central IRB #H-39846/ NHLB #SCD-CARRE: Sickle Cell Disease & CardiovAscular Risk – Red cell Exchange Trial

Central IRB #H-40856/ Forma #4202-HEM-301 (HIBISCUS): An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Agonist in Patients with Sickle Cell Disease (HIBISCUS) (pending IRB approval)